The clinical role of procalcitonin in hematopoietic SCT

Bone Marrow Transplantation

Volumn 47, Issue 10, 2012, Pages 1326-1331

  Koya, J ^a   Nannya, Y ^a   Ichikawa, M ^a   Kurokawa, M ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Differential diagnosis; Hematopoietic SCT; Infection; Procalcitonin; Transplantation related complication

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADENOVIRUS INFECTION; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DIFFERENTIAL DIAGNOSIS; ENGRAFTMENT SYNDROME; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES VIRUS INFECTION; HORMONE BLOOD LEVEL; HUMAN; HUMAN HERPESVIRUS 6; INFECTION; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PYREXIA IDIOPATHICA; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SYSTEMIC MYCOSIS; TUBERCULOSIS;

BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MYCOSES; PROTEIN PRECURSORS;

EID: 84867401532     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.18     Document Type: Article

References (31)

1. Schwaighofer H, Herold M, Schwarz T, Nordberg J, Ceska M, Prior C et al. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation 1994; 58: 430-436.
2. Pihusch M, Pihusch R, Fraunberger P, Pihusch V, Andreesen R, Kolb HJ et al. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 2006; 76: 93-101.
3. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-217.
4. Limper M, de Kruif MD, Duits AJ, Brandjes DP, van Gorp EC. The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from noninfectious fever. J Infect 2010; 60: 409-416.
5. Reinhart K, Carlet J. Procalcitonin-a new marker of severe infection and sepsis. Intensive Care Med 2000; 26(Suppl 2): S145.
6. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607.
7. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059-1066.
8. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93.
9. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177: 498-505.
10. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 2001; 32: 1718-1725.
11. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008; 36: 396-407.
12. Blijlevens NM, Donnelly JP, Meis JF, De Keizer MH, De Pauw BE. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol 2000; 7: 889-892.
13. Ortega M, Rovira M, Filella X, Almela M, Puig de la Bellacasa J, Carreras E et al. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol 2004; 126: 372-376.
14. Hambach L, Eder M, Dammann E, Schrauder A, Sykora KW, Dieterich C et al. Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. Haematologica 2002; 87: 643-651.
15. Azarpira N, Ramzi M, Aghdaie M, Daraie M. Procalcitonin and C-reactive protein serum levels after hematopoietic stem-cell transplant. Exp Clin Transplant 2009; 7: 115-118.
16. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
17. Kanda Y, Mineishi S, Saito T, Saito A, Ohnishi M, Niiya H et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation 2002; 73: 568-572.
18. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
19. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
20. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset noninfectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 425-434.
21. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-575.
22. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-898.
23. Leadership members of the American College of Chest Physicians/Society of Critical Care Medicine. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
24. Brodska H, Drabek T, Malickova K, Kazda A, Vitek A, Zima T et al. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care 2009; 13: R37.
25. Gendrel D, Bohuon C. Procalcitonin in pediatrics for differentiation of bacterial and viral infections. Intensive Care Med 2000; 26 (Suppl 2): S178-S181.
26. Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001; 84: 332-336.
27. Nyamande K, Lalloo UG. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 2006; 10: 510-515.
28. Sarmati L, Beltrame A, Dori L, Maffongelli G, Cudillo L, De Angelis G et al. Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. Am J Hematol 2010; 85: 380-383.
29. Sauer M, Tiede K, Fuchs D, Gruhn B, Berger D, Zintl F. Procalcitonin, C-reactive protein, and endotoxin after bone marrow transplantation: identification of children at high risk of morbidity and mortality from sepsis. Bone Marrow Transplant 2003; 31: 1137-1142.
30. Semeraro M, Thomee C, Rolland E, Le Deley MC, Rosselini D, Troalen F et al. A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin. Pediatr Blood Cancer 2010; 54: 284-290.
31. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-e93.